Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(23):475.
doi: 10.21037/atm.2017.10.09.

Semaglutide-the " new kid on the block" in the field of glucagon-like peptide-1 receptor agonists?

Cristian Guja  1   2 , Rucsandra Dănciulescu Miulescu  1   2
Affiliations
Editorial

Semaglutide-the " new kid on the block" in the field of glucagon-like peptide-1 receptor agonists?

Cristian Guja et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: C Guja has received consulting fees from Alfa Wasserman, AstraZeneca, Bayer AG, Berlin-Chemie Mennarini, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi. R Dănciulescu Miulescu has no conflicts of interest to declare.

Comment on

References

    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9 10.2337/dc14-2441 - DOI - PubMed
    1. American Diabetes Association Pharmacologic approaches to glycemic treatment. sec. 8. in standards of medical care in Diabetes-2017. Diabetes Care 2017;40:S64-S74. - PubMed
    1. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015;6:19-28. 10.1177/2042018814559725 - DOI - PMC - PubMed
    1. ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia 2015;58:2688-98. 10.1007/s00125-015-3754-x - DOI - PMC - PubMed
    1. Abd El Aziz MS, Kahle M, Meier JJ, et al. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017;19:216-27. 10.1111/dom.12804 - DOI - PubMed

LinkOut - more resources